Vascular Biogenics Ltd - ESG Rating & Company Profile powered by AI
Scroll down to the end of this page for potential risks for Vascular Biogenics Ltd based on sector, geography and size. The Disclosure rating includes 17 United Nations SDGs including: 'Gender Equality', 'Decent Work & Economic Growth' and 'Peace, Justice & Strong Institutions'. This ESG assessment for Vascular Biogenics Ltd indicates the company's reporting of the UN SDGs.
Vascular Biogenics Ltd in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 4.7; made up of an environmental score of 5.3, social score of 4.8 and governance score of 4.0.
4.7
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| 816 | Pliant Therapeutics Inc | 4.8 | High |
| 816 | Voyager Therapeutics Inc | 4.8 | High |
| 837 | Vascular Biogenics Ltd | 4.7 | High |
| 837 | Bio Rad Laboratories Inc | 4.7 | High |
| 837 | Katakura Industries Co Ltd | 4.7 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Vascular Biogenics Ltd have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Vascular Biogenics Ltd disclose current and historical energy intensity?
Sign up for free to unlockDoes Vascular Biogenics Ltd report the average age of the workforce?
Sign up for free to unlockDoes Vascular Biogenics Ltd reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Vascular Biogenics Ltd disclose its ethnicity pay gap?
Sign up for free to unlockDoes Vascular Biogenics Ltd disclose cybersecurity risks?
Sign up for free to unlockDoes Vascular Biogenics Ltd offer flexible work?
Sign up for free to unlockDoes Vascular Biogenics Ltd have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Vascular Biogenics Ltd disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Vascular Biogenics Ltd conduct supply chain audits?
Sign up for free to unlockDoes Vascular Biogenics Ltd disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Vascular Biogenics Ltd conduct 360 degree staff reviews?
Sign up for free to unlockDoes Vascular Biogenics Ltd disclose the individual responsible for D&I?
Sign up for free to unlockDoes Vascular Biogenics Ltd disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Vascular Biogenics Ltd disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Vascular Biogenics Ltd disclose water use targets?
Sign up for free to unlockDoes Vascular Biogenics Ltd have careers partnerships with academic institutions?
Sign up for free to unlockDid Vascular Biogenics Ltd have a product recall in the last two years?
Sign up for free to unlockDoes Vascular Biogenics Ltd disclose incidents of discrimination?
Sign up for free to unlockDoes Vascular Biogenics Ltd allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Vascular Biogenics Ltd issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Vascular Biogenics Ltd disclose parental leave metrics?
Sign up for free to unlockDoes Vascular Biogenics Ltd disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Vascular Biogenics Ltd disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Vascular Biogenics Ltd disclose the pay ratio of women to men?
Sign up for free to unlockDoes Vascular Biogenics Ltd support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Vascular Biogenics Ltd disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Vascular Biogenics Ltd reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Vascular Biogenics Ltd involved in embryonic stem cell research?
Sign up for free to unlockDoes Vascular Biogenics Ltd disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Vascular Biogenics Ltd disclose its waste policy?
Sign up for free to unlockDoes Vascular Biogenics Ltd report according to TCFD requirements?
Sign up for free to unlockDoes Vascular Biogenics Ltd disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Vascular Biogenics Ltd disclose energy use targets?
Sign up for free to unlockDoes Vascular Biogenics Ltd disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Vascular Biogenics Ltd have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Vascular Biogenics Ltd
These potential risks are based on the size, segment and geographies of the company.
Vascular Biogenics Ltd., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. Its programs are based on its vascular targeting system, a gene-based technology targeting newly formed blood vessels; and monocyte targeting technology, an antibody-based technology that enables specifically inhibit monocyte migration for immune-inflammatory applications. The company's lead product candidate is VB-111, a gene-based biologic that is in Phase III clinical trials for the recurrent platinum-resistant ovarian cancer; and Phase II clinical trials treatment of recurrent glioblastoma and colorectal cancer, as well as has completed Phase II clinical trial for the treatment of thyroid cancer. It is also developing VB-601 for various inflammatory indications, and VB-611 for various solid tumors. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was incorporated in 2000 and is headquartered in Modi'in, Israel.